Company news

Galderma Group AG news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Galderma Launches Alastin® in China, Supporting the Skin’s Natural Regenerative Abilities in a Rapidly Expanding Market

September 10, 2025

Galderma Delivers Record First Half 2025 Net Sales of 2.448 Billion USD and 12.2% Year-on-Year Growth at Constant Currency, Raises Full-Year Top-Line Guidance

July 24, 2025

Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss

July 17, 2025

Galderma Announces Departure of Its Chief Financial Officer

July 1, 2025

Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin

June 25, 2025

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

June 18, 2025

Galderma’s Nemluvio® (nemolizumab) Receives National Institute for Health and Care Excellence (NICE) Recommendation for Moderate-to-severe Atopic Dermatitis in England and Wales

June 12, 2025

RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years

June 6, 2025

Galderma Buys Back Shares Worth CHF 233 Million in the Context of Accelerated Bookbuild Offering

May 28, 2025

Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba

May 27, 2025

Galderma Delivers Record First Quarter Net Sales of 1.129 Billion USD, Including Strong Performance From Two Launches With Blockbuster Potential, and Confirms Full-Year Guidance

April 24, 2025

Galderma launches new ALASTIN Restorative Skin Complex with Next Generation TriHex Technology®

April 17, 2025

Galderma Launches Sculptra® in China, Further Fueling Its Growth Into One of the Fastest Growing Aesthetics Markets

April 15, 2025

AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community

March 20, 2025

Galderma's Differin is helping destigmatize acne care with first in category Roblox experience

March 17, 2025

Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency1, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond

March 6, 2025

AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum

March 3, 2025

Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

February 18, 2025

← Newer news releases

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.